Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical animal studies and mechanistic data.
PubMed 22300085 · doi:10.2174/092986712803414015
What was done
This is a narrative review summarizing preclinical pharmacology, animal disease models (intestinal anastomosis healing, short bowel syndrome, fistula healing), and mechanistic pathways of the pentadecapeptide BPC 157 for inflammatory bowel disease and ulcerative colitis, alongside a mention of early phase II clinical testing.
What was found
The abstract provides no numerical data, effect sizes, or statistical metrics. It qualitatively reports that BPC 157 is stable in human gastric juice, modulates the nitric oxide system, stimulates early growth response 1 gene expression and extracellular matrix formation, promotes angiogenesis, and showed safety in animal toxicity tests (limit test negative, LD1 not achieved).
Why it matters
The paper outlines the proposed mechanistic rationale and animal evidence for BPC 157 as a potential candidate for gastrointestinal wound healing and inflammatory bowel disease.
Limits
The abstract reports no quantitative clinical trial data, sample sizes, or outcome metrics. The findings rely predominantly on animal models, with minimal and non-detailed reference to human clinical trial data.
Cited by
- partial A Croatian clinical trial evaluated rectal enemas of BPC-157 at doses up to 80 milligrams in patients with ulcerative colitis, finding no adverse events in phase 1 and absence of systemic drug levels in the blood.